MUMBAI, October 31, 2013 /PRNewswire/ --
Net Profit for the second quarter was Rs 1542.97 Mn as compared to Rs. 1567.52 mn for the previous corresponding quarter
Highlights: Q2-FY14 -Results
Glenmark Pharmaceuticals Limited (GPL), the research-led global integrated pharmaceutical company announced its results for the second quarter ended September 30, 2013
For the second quarter ended Sep 30, 2013, Glenmark's consolidated revenue was at Rs. 14630.06 Mn (USD 235.62 Mn ) as against Rs. 12551.91Mn (USD 227.89 Mn) an increase of 16.56 % .
Revenue from the generics business was at Rs.7106.55Mn (USD 114.20Mn) as against Rs. 5800.78 Mn (USD 105.27 Mn), growth of 22.51 %. The Specialty formulation business excluding out-licensing revenue was atRs.7405.41Mn (USD 119.42Mn) as against Rs. 6751.13 Mn (USD 122.62 Mn) for the corresponding previous quarter, recording a growth of 9.69%.
Net Profit (after taxes and minority interests) for the second quarter was Rs 1542.97 Mn as compared to Rs. 1567.52 Mn for the previous corresponding quarter
"Despite challenges in the operating environment, we have managed to register decent sales growth of 17% on the back of good performances by our USand Indiabusinesses. We have been also making steady progress on the Innovation R&D front with our 4 NCE & NBE molecules in clinical trials"; said Glenn Saldanha, Chairman &a
|SOURCE Glenmark Pharmaceuticals Ltd|
Copyright©2012 PR Newswire.
All rights reserved